` ALDX (Aldeyra Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

ALDX
vs
S&P 500

Over the past 12 months, ALDX has underperformed S&P 500, delivering a return of -6% compared to the S&P 500's +14% growth.

Stocks Performance
ALDX vs S&P 500

Loading
ALDX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ALDX vs S&P 500

Performance Gap Between ALDX and GSPC
HIDDEN
Show

Performance By Year
ALDX vs S&P 500

Loading
ALDX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Aldeyra Therapeutics Inc vs Peers

S&P 500
ALDX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Aldeyra Therapeutics Inc
Glance View

Market Cap
276.1m USD
Industry
Biotechnology

Aldeyra Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Lexington, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2014-05-02. The firm's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). The company has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The firm's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses two biological mechanisms of action: reactive aldehyde species (RASP) modulation and dihydrofolate reductase inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation through down-regulation of immune cell activation or proliferation.

ALDX Intrinsic Value
HIDDEN
Show
Back to Top